SIALIC ACID MODULATION REGULATES NEUTROPHIL DIAPEDESIS
SIALIC ACID MODULATION REGULATES NEUTROPHIL DIAPEDESIS
批准号:
6341703
负责人:
Alan S. Cross
金额:
$25.25万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-01-01 至 2002-12-31
关键词:
T lymphocyte cell adhesion cell cell interaction cell migration cytotoxicity enzyme activity enzyme inhibitors exo alpha sialidase free radical oxygen gene expression genetic regulation human tissue immunoprecipitation interleukin 8 leukocyte activation /transformation lymphoblast neutrophil nitric oxide nucleic acid sequence protein purification selectins sialate sialyltransferases tissue /cell culture vascular endothelium
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Adapted from the applicant's abstract): Sialic acids are
amino sugars that are present on mammalian cells as glycoconjugates and
impart to these cells a negative surface charge. The loss of sialic acid
occurs during both myeloid maturation and activation and is accompanied
by enhanced motility, deformability and adhesiveness. Sialidases are
enzymes that rapidly remove sialic acid residues from glycoconjugates
and on neutrophil activation are rapidly mobilized to plasma membrane.
In contrast, by adding sialic acid residues back onto glycoconjugates,
sialyltransferases (ST) may restore glycoconjugates to the preactivated
state. Thus, the amount and distribution of sialic acid residues on both
neutrophils and perhaps endothelial cells (EC) may represent a rapidly
adaptable mechanism by which neutrophils respond to local inflammatory
stimuli and leave the circulation. In Specific Aim I the PI will examine
the effect of sialic acid modulation at each stage of neutrophil
diapedeis: rolling adhesion, firm adhesion and transendothelial
migration (TEM). Resting or activated human neutrophils will be added
to EC monolayers that are either resting or activated with short-acting
(histamine) or long acting (TNF) stimuli or treated with
neutroaminidase. Neutrophil adherence and TEM will be measured in
response to either IL-8 or to buffer (spontaneous). The role of PMN
sialidase will be assessed with the use of pharmacologic inhibitors of
sialidase and a polyclonal antisialidase antibody previously shown to
inhibit neutrophil sialidase. The expression of PMN ST relative to
sialidase will be determined. In Specific Aim II the applicant will
determine the role of sialic acid modulation of EC monolayers in
neutrophil adherence and TEM. Preliminary evidence for an endogenous EC
sialidase will be extended by both enzymatic activity and immune
detection. in Specific AIM III he will determine the degree of homology
of neutrophil sialidase with a recently described human sialidase cloned
from the MHC region of lymphoblastoid cells and which may play a role
in T cell activation. Neutrophil sialidase will be purified and
sequenced from lysates eluded from antisialidase antibody bound to a
solid matrix. These sequences will be used to construct primers from
cloning of the sialidase from a human HL-60 cell library. Endothelial
cell sialidase will be isolated, cloned and compared to neutrophil
sialidase in Aim III. These studies will define a new mechanism for a
rapidly adaptable, temporally- restricted local response to
inflammation. This proposal will provide new targets and additional
approaches to the treatment of inflammation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of a prototype Klebsiella O polysaccharide conjugate vaccine
-
批准号:9089850
-
项目类别:
-
资助金额:$19.19万
-
财政年份:2015
-
负责人:Alan S. Cross
-
依托单位:
Development of a prototype Klebsiella O polysaccharide conjugate vaccine
-
批准号:8841098
-
项目类别:
-
资助金额:$23.03万
-
财政年份:2015
-
负责人:Alan S. Cross
-
依托单位:
Novel peptide antagonist theraphy for superantigen- induced lethal shock
-
批准号:8233382
-
项目类别:
-
资助金额:$23.62万
-
财政年份:2011
-
负责人:Alan S. Cross
-
依托单位:
Novel peptide antagonist theraphy for superantigen- induced lethal shock
-
批准号:7670085
-
项目类别:
-
资助金额:$23.26万
-
财政年份:2009
-
负责人:Alan S. Cross
-
依托单位:
Tularemia
-
批准号:7678793
-
项目类别:
-
资助金额:$35.32万
-
财政年份:2008
-
负责人:Alan S. Cross
-
依托单位:
Role of Sialidase in Pulmonary Host Defenses and Acute Lung Injury
-
批准号:7637431
-
项目类别:
-
资助金额:$46.7万
-
财政年份:2007
-
负责人:Alan S. Cross
-
依托单位:
Role of Sialidase in Pulmonary Host Defenses and Acute Lung Injury
-
批准号:7866681
-
项目类别:
-
资助金额:$46.82万
-
财政年份:2007
-
负责人:Alan S. Cross
-
依托单位:
Role of Sialidase in Pulmonary Host Defenses and Acute Lung Injury
-
批准号:7318032
-
项目类别:
-
资助金额:$42.87万
-
财政年份:2007
-
负责人:Alan S. Cross
-
依托单位:
Role of Sialidase in Pulmonary Host Defenses and Acute Lung Injury
-
批准号:7477660
-
项目类别:
-
资助金额:$45.63万
-
财政年份:2007
-
负责人:Alan S. Cross
-
依托单位:
Early events during infection with anthrax
-
批准号:6873824
-
项目类别:
-
资助金额:$22.03万
-
财政年份:2005
-
负责人:Alan S. Cross
-
依托单位:
Early events during infection with anthrax
-
批准号:7028848
-
项目类别:
-
资助金额:$18.13万
-
财政年份:2005
-
负责人:Alan S. Cross
-
依托单位:
Evaluation of Anti-endotoxin Vaccine for Human Use
-
批准号:6475133
-
项目类别:
-
资助金额:$39.84万
-
财政年份:2002
-
负责人:Alan S. Cross
-
依托单位:
EVALUATION OF ANTIENDOTOXIN VACCINE FOR HUMAN USE
-
批准号:2842036
-
项目类别:
-
资助金额:$36.79万
-
财政年份:1999
-
负责人:Alan S. Cross
-
依托单位:
EVALUATION OF ANTIENDOTOXIN VACCINE FOR HUMAN USE
-
批准号:6373743
-
项目类别:
-
资助金额:$30.67万
-
财政年份:1999
-
负责人:Alan S. Cross
-
依托单位:
Evaluation of Anti-endotoxin Vaccine for Human Use
-
批准号:7061703
-
项目类别:
-
资助金额:$39.51万
-
财政年份:1999
-
负责人:Alan S. Cross
-
依托单位:
Evaluation of Anti-endotoxin Vaccine for Human Use
-
批准号:6891346
-
项目类别:
-
资助金额:$38.68万
-
财政年份:1999
-
负责人:Alan S. Cross
-
依托单位:
Evaluation of Anti-endotoxin Vaccine for Human Use
-
批准号:6573675
-
项目类别:
-
资助金额:$19.14万
-
财政年份:1999
-
负责人:Alan S. Cross
-
依托单位:
SIALIC ACID MODULATION REGULATES NEUTROPHIL DIAPEDESIS
-
批准号:6488706
-
项目类别:
-
资助金额:$25.74万
-
财政年份:1999
-
负责人:Alan S. Cross
-
依托单位:
Evaluation of Anti-endotoxin Vaccine for Human Use
-
批准号:6747863
-
项目类别:
-
资助金额:$33.2万
-
财政年份:1999
-
负责人:Alan S. Cross
-
依托单位:
EVALUATION OF ANTIENDOTOXIN VACCINE FOR HUMAN USE
-
批准号:6171094
-
项目类别:
-
资助金额:$29.95万
-
财政年份:1999
-
负责人:Alan S. Cross
-
依托单位:
国内基金
海外基金
GMFG/F-actin/cell adhesion 轴驱动 EHT 在造
血干细胞生成中的作用及机制研究
-
批准号:TGY24H080011
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:李鸿鹄
-
依托单位: